165 related articles for article (PubMed ID: 10597379)
1. Gene-modified immunotherapy for renal cell carcinoma.
Kawai K; Tani K; Asano S; Akaza H
Contrib Nephrol; 1999; 128():75-81. PubMed ID: 10597379
[No Abstract] [Full Text] [Related]
2. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
Chaudhary UB; Hull GW
Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
[TBL] [Abstract][Full Text] [Related]
3. [Current modalities in immunotherapy of renal cell carcinoma].
Aliaev IuG; Grigorian VA; Shpot' EV
Ter Arkh; 2007; 79(6):78-82. PubMed ID: 17684975
[No Abstract] [Full Text] [Related]
4. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
Bex A; Horenblas S; de Gast GC
Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Rupp NJ; Mischo A; Moch H
Ther Umsch; 2017 Sep; 74(4):171-179. PubMed ID: 28950771
[No Abstract] [Full Text] [Related]
6. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
Schmitz-Dräger BJ; Jankevicius F; Otto T
Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
[TBL] [Abstract][Full Text] [Related]
7. Biomarker classification, validation, and what to look for in 2017 and beyond.
Davis JW
BJU Int; 2017 May; 119(5):812-814. PubMed ID: 28117555
[No Abstract] [Full Text] [Related]
8. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.
Négrier S
J Clin Oncol; 2004 Apr; 22(7):1174-6. PubMed ID: 14981101
[No Abstract] [Full Text] [Related]
9. Prognostic factors of immunotherapy in metastatic renal cell carcinoma.
Padrik P
Med Oncol; 2003; 20(4):325-34. PubMed ID: 14716028
[TBL] [Abstract][Full Text] [Related]
10. Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols.
Favrot MC; Puisieux I
Adv Exp Med Biol; 1998; 451():539-41. PubMed ID: 10026924
[No Abstract] [Full Text] [Related]
11. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma.
Motzer RJ
Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S33-9. PubMed ID: 12850525
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
[TBL] [Abstract][Full Text] [Related]
13. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
Pantuck AJ; Belldegrun AS; Figlin RA
N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
[No Abstract] [Full Text] [Related]
14. Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer.
Boursnell ME; Entwisle C; Ali SA; Sivasubramaniam SD; Reeder S; McLean CS; Blakeley DM; Miller J; Hill S; Shields JG; Inglis SC; Rees RC
Adv Exp Med Biol; 1998; 451():379-84. PubMed ID: 10026900
[No Abstract] [Full Text] [Related]
15. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma and interleukin-2: what are the endpoints?
Figlin RA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S68-9. PubMed ID: 9457397
[No Abstract] [Full Text] [Related]
17. Allogeneic stem cell transplantation for renal cell carcinoma.
Childs R; Drachenberg D
Curr Opin Urol; 2001 Sep; 11(5):495-502. PubMed ID: 11493771
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for renal cell carcinoma.
Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
[TBL] [Abstract][Full Text] [Related]
19. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
Schmitz-Dräger BJ
Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
[No Abstract] [Full Text] [Related]
20. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
